Hytrin, 2 mg, 5 mg, 10 mg, tablets
Terazosin
One tablet of 2 mg, 5 mg or 10 mg of Hytrin contains 2 mg, 5 mg or 10 mg of the active substance - terazosin, in the form of terazosin hydrochloride dihydrate.
Hytrin belongs to a group of medicines called alpha-adrenergic blockers (medicines used to treat conditions such as high blood pressure and certain prostate diseases).
Hytrin relieves the symptoms of benign prostatic hyperplasia. In combination with other blood pressure lowering medicines, it can also be used to treat high blood pressure.
Benign prostatic hyperplasia: Hytrin relaxes the muscles of the prostate gland, which surrounds the inner part of the urethra in men. This makes it easier to urinate, and the symptoms are relieved.
High blood pressure: Hytrin lowers blood pressure by widening small blood vessels (located away from the heart). This reduces the resistance to blood pumping by the heart. Hytrin does not act directly on the blood vessel walls. It acts on the nerves that affect the blood vessels.
Hytrin is intended for adults from 18 to 64 years old.
Before starting to take Hytrin, discuss it with your doctor or pharmacist.
In order to minimize the risk of fainting or severe hypotension, treatment should always start with a dose of 1 mg of terazosin from other companies, given in the evening, after going to bed. Tablets containing 2 mg, 5 mg or 10 mg of terazosin are not recommended during the initial treatment period. The dose should be gradually increased, according to the recommendations given in section 3.
The patient should be warned to avoid situations that may lead to injury in case of fainting during the initial treatment period. If fainting occurs, the patient should be laid down, and if necessary, the doctor will provide supportive treatment.
Hytrin should not be used in patients who have experienced fainting during urination.
If laboratory tests are to be performed, inform your doctor that you are taking Hytrin, as the medicine may interfere with the results of some tests.
If you are taking other medicines, also read the section "Hytrin and other medicines".
If you are taking other blood pressure lowering medicines, such as captopril, lisinopril, thiazide diuretics and calcium antagonists (amlodipine, diltiazem).
If you are taking such medicines as labetalol and carvedilol for the treatment of angina pectoris or irregular heartbeat.
If Hytrin is used with phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil and vardenafil [these medicines are used to treat erectile dysfunction (impotence) and chronic heart failure], a significant decrease in blood pressure may occur. However, to minimize the risk of these symptoms, a fixed daily dose of alpha-adrenergic blockers should be taken, and medicines used to treat erectile dysfunction should be taken 4 hours later.
In order to limit the risk of orthostatic hypotension before starting the use of phosphodiesterase type 5 inhibitors, the patient should first have a regular dose of Hytrin established.
Breastfeeding
It is not known whether terazosin hydrochloride passes into breast milk. Since many medicines pass into breast milk, caution should be exercised when using Hytrin in breastfeeding women.
Avoid driving vehicles, performing hazardous work and operating machinery, unless it has been shown that the medicine does not affect the patient's physical and mental abilities.
Hytrin contains lactose. If you have an intolerance to some sugars, consult your doctor before taking the medicine.
This medicine should always be taken exactly as directed by your doctor. If you are unsure, consult your doctor.
The following information provides general recommendations for the use of Hytrin.
The initial dose is 1 mg of terazosin from other companies, once a day, in the evening, after going to bed. Do not take a higher dose. During the initial treatment period, this dosing regimen should be strictly followed to minimize the risk of severe hypotension.
The dose should be gradually increased until the desired clinical response is achieved. The recommended dose range is 5 to 10 mg once a day. The flow rate of urine measured about 24 hours after the last dose showed that in benign prostatic hyperplasia, the beneficial effect is maintained throughout the dosing interval. A reduction in the severity of symptoms was observed after 2 weeks of treatment with terazosin hydrochloride. The improvement in urine flow rate occurs slightly later. If terazosin hydrochloride is discontinued for several days or longer, treatment should be resumed with the initial dose.
The dose should be gradually increased until the desired blood pressure reduction is achieved. The recommended dose range is 1 to 5 mg once a day, although in some patients a dose of 20 mg/day may be required. It does not appear that doses higher than 20 mg produce further blood pressure reduction. Doses higher than 40 mg have not been studied. Before taking the next dose of the medicine, blood pressure should be regularly measured to check if blood pressure control is maintained throughout the day. It may also be helpful to measure blood pressure 2 to 3 hours after taking the dose to check if the maximum and minimum responses to the medicine are similar, as well as to record symptoms such as dizziness or palpitations, which may be caused by excessive blood pressure reduction. If after 24 hours there is a significant decrease in the therapeutic effect, it may be necessary to increase the dose of the medicine or take it twice a day. If terazosin hydrochloride is discontinued for several days or longer, treatment should be resumed with the initial dose. In clinical studies, the medicine was given in the morning, except for the initial dose.
In elderly patients, lower doses should be used than in other adult patients. In elderly patients, there is a higher risk of side effects. The doctor will provide detailed information on the exact dosing and close monitoring.
Due to the lack of data on the efficacy and safety of Hytrin, it is not recommended to use the medicine in children and adolescents.
Oral administration: Hytrin tablets should be swallowed whole, with a sufficient amount of liquid. The tablets should not be chewed. They can be taken with food.
Patients usually need to take Hytrin for several weeks before they start to feel relief from symptoms. Do not stop taking the medicine without consulting your doctor. The doctor will probably recommend gradually reducing the dose before completely stopping the medicine. This will prevent the patient's condition from worsening and reduce the risk of withdrawal symptoms, such as headache, nausea, vomiting, diarrhea, insomnia, nervousness and anxiety.
If you have taken more than the recommended dose of Hytrin or someone else has taken the medicine, the patient should be laid down with their feet elevated relative to the body. Immediately seek help from the nearest hospital emergency department. Take any remaining tablets or the empty package of the medicine with you to show the doctor.
Taking too many tablets may cause excessive blood pressure reduction, with fainting, sudden loss of consciousness and rapid heartbeat, as well as other severe side effects described in section 4. Possible side effects.
If you miss a dose of Hytrin, you can take it as soon as possible, unless it is time for the next dose. In this case, take the medicine as recommended. Do not take a double dose to make up for the missed dose. Do not take more than one tablet per day.
If you stop treatment for several days or longer, you should start again after consulting your doctor, starting with the initial dose.
Do not stop taking Hytrin without your doctor's advice.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Hytrin can cause side effects, although not everybody gets them.
Some side effects can be serious:
If you experience any of these symptoms, tell your doctor immediately, as it may be necessary to adjust the dose of the medicine.
The following side effects may occur as a result of taking terazosin hydrochloride. When evaluating side effects, the following frequencies were taken into account:
Common side effects(may occur in less than 10 patients in 100):
Uncommon(may occur in 1 patient in 100):
Rare(may occur in less than 10 patients in 10,000):
Unknown(frequency cannot be estimated from the available data):
If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products,
Al. Jerozolimskie 181C, 02-222 Warsaw,
phone: +48 22 49-21-301,
fax: +48 22 49-21-309,
e-mail: ndl@urpl.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Store in a temperature below 25°C.
Keep the medicine out of the sight and reach of children.
Do not use Hytrin after the expiry date stated on the packaging.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The 2 mg tablet of Hytrin is yellow.
The 5 mg tablet of Hytrin is light brown.
The 10 mg tablet of Hytrin is blue.
Hytrin 2 mg tablets
(Continuation of treatment)
28 tablets - 2 blisters of 14 tablets each.
Hytrin 5 mg tablets
(Continuation of treatment)
28 tablets - 2 blisters of 14 tablets each.
Hytrin 10 mg tablets
(Continuation of treatment)
28 tablets - 2 blisters of 14 tablets each.
Blisters made of PVC/PVDC/Aluminum in a cardboard box.
Amdipharm Limited
Temple Chambers
3 Burlington Road
Dublin 4
Ireland
Manufacturer:
AESICA QUEENBOROUGH LIMITED
Queenborough, Kent
ME11 5EL
United Kingdom
Or
Famar Italia S.p.A.
Via Zambeletti, 25
20021 Baranzate (Milano)
Italy
Or
Aesica Pharmaceuticals S.r.L.
Via Praglia, 15
10044 Pianezza
Italy
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.